CN100374121C - Tillering onion extract and its application - Google Patents
Tillering onion extract and its application Download PDFInfo
- Publication number
- CN100374121C CN100374121C CNB031270336A CN03127033A CN100374121C CN 100374121 C CN100374121 C CN 100374121C CN B031270336 A CNB031270336 A CN B031270336A CN 03127033 A CN03127033 A CN 03127033A CN 100374121 C CN100374121 C CN 100374121C
- Authority
- CN
- China
- Prior art keywords
- multiplieronion
- abstract
- extract
- fat
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940072113 onion extract Drugs 0.000 title description 2
- 239000000284 extract Substances 0.000 claims abstract description 50
- 210000004369 blood Anatomy 0.000 claims abstract description 22
- 239000008280 blood Substances 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 208000011775 arteriosclerosis disease Diseases 0.000 claims abstract description 8
- 244000053852 Allium cepa var. aggregatum Species 0.000 claims description 85
- 235000010167 Allium cepa var aggregatum Nutrition 0.000 claims description 75
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 59
- -1 flavone compound Chemical class 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 27
- 239000011347 resin Substances 0.000 claims description 20
- 229920005989 resin Polymers 0.000 claims description 20
- 229930003944 flavone Natural products 0.000 claims description 17
- 235000011949 flavones Nutrition 0.000 claims description 17
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 claims description 15
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 12
- 239000003463 adsorbent Substances 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 12
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 12
- 230000003637 steroidlike Effects 0.000 claims description 11
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 7
- 238000010828 elution Methods 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 7
- 239000003146 anticoagulant agent Substances 0.000 claims description 6
- 238000007598 dipping method Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 238000010266 Sephadex chromatography Methods 0.000 claims description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 238000004220 aggregation Methods 0.000 claims description 5
- 230000002776 aggregation Effects 0.000 claims description 5
- 230000000702 anti-platelet effect Effects 0.000 claims description 5
- 229920002401 polyacrylamide Polymers 0.000 claims description 5
- 239000000741 silica gel Substances 0.000 claims description 5
- 229910002027 silica gel Inorganic materials 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 4
- 239000004952 Polyamide Substances 0.000 claims description 3
- 229920002647 polyamide Polymers 0.000 claims description 3
- 230000033228 biological regulation Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 241000234282 Allium Species 0.000 abstract description 13
- 241000234280 Liliaceae Species 0.000 abstract description 6
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 235000002732 Allium cepa var. cepa Nutrition 0.000 abstract 2
- 230000004520 agglutination Effects 0.000 abstract 1
- 210000001772 blood platelet Anatomy 0.000 abstract 1
- 235000019197 fats Nutrition 0.000 description 54
- 241001465754 Metazoa Species 0.000 description 33
- 230000037396 body weight Effects 0.000 description 20
- 241000700159 Rattus Species 0.000 description 18
- 210000004185 liver Anatomy 0.000 description 15
- 108010023302 HDL Cholesterol Proteins 0.000 description 14
- 210000002966 serum Anatomy 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 208000031226 Hyperlipidaemia Diseases 0.000 description 13
- 108010028554 LDL Cholesterol Proteins 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 208000008589 Obesity Diseases 0.000 description 9
- 235000020824 obesity Nutrition 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- 102000019197 Superoxide Dismutase Human genes 0.000 description 8
- 108010012715 Superoxide dismutase Proteins 0.000 description 8
- 229910052717 sulfur Inorganic materials 0.000 description 8
- 239000003480 eluent Substances 0.000 description 7
- QMQIQBOGXYYATH-UHFFFAOYSA-N epiruscogenin Natural products CC1C(C2(CCC3C4(C)C(O)CC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 QMQIQBOGXYYATH-UHFFFAOYSA-N 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 229940080794 lovastatin 20 mg Drugs 0.000 description 6
- 210000002381 plasma Anatomy 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 150000002213 flavones Chemical class 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 210000004392 genitalia Anatomy 0.000 description 5
- 235000021590 normal diet Nutrition 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000000501 Lipidoses Diseases 0.000 description 3
- 206010024585 Lipidosis Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000000825 ultraviolet detection Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000282894 Sus scrofa domesticus Species 0.000 description 2
- NAXKFVIRJICPAO-LHNWDKRHSA-N [(1R,3S,4R,6R,7R,9S,10S,12R,13S,15S,16R,18S,19S,21S,22S,24S,25S,27S,28R,30R,31R,33S,34S,36R,37R,39R,40S,42R,44R,46S,48S,50R,52S,54S,56S)-46,48,50,52,54,56-hexakis(hydroxymethyl)-2,8,14,20,26,32,38,43,45,47,49,51,53,55-tetradecaoxa-5,11,17,23,29,35,41-heptathiapentadecacyclo[37.3.2.23,7.29,13.215,19.221,25.227,31.233,37.04,6.010,12.016,18.022,24.028,30.034,36.040,42]hexapentacontan-44-yl]methanol Chemical compound OC[C@H]1O[C@H]2O[C@H]3[C@H](CO)O[C@H](O[C@H]4[C@H](CO)O[C@H](O[C@@H]5[C@@H](CO)O[C@H](O[C@H]6[C@H](CO)O[C@H](O[C@H]7[C@H](CO)O[C@@H](O[C@H]8[C@H](CO)O[C@@H](O[C@@H]1[C@@H]1S[C@@H]21)[C@@H]1S[C@H]81)[C@H]1S[C@@H]71)[C@H]1S[C@H]61)[C@H]1S[C@@H]51)[C@H]1S[C@@H]41)[C@H]1S[C@H]31 NAXKFVIRJICPAO-LHNWDKRHSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000000274 adsorptive effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 2
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 229960004844 lovastatin Drugs 0.000 description 2
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920006122 polyamide resin Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000007863 steatosis Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- BGKHCLZFGPIKKU-UHFFFAOYSA-N (13E,15S)-15-hydroxy-9-oxo-prosta-10,13-dienoic acid Natural products CCCCCC(O)C=CC1C=CC(=O)C1CCCCCCC(O)=O BGKHCLZFGPIKKU-UHFFFAOYSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000005255 Allium cepa Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920001268 Cholestyramine Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- KNDHRUPPBXRELB-UHFFFAOYSA-M [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride Chemical compound [Cl-].C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 KNDHRUPPBXRELB-UHFFFAOYSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 description 1
- 235000010081 allicin Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001678 colestyramine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000880 dysequilibrium Toxicity 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940089491 hydroxycitric acid Drugs 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 229940011964 pentobarbital sodium 30 mg Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229960002662 propylthiouracil Drugs 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000013456 study Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a tillering onion which belongs to an allium in a lily family, particularly to a non-volatile extract product of the tillering onion, a preparation method thereof, and application of the extract product for preparing medicine used for reducing weight, regulating blood fat, resisting agglutination of blood platelets and resisting arterial sclerosis.
Description
The affiliated field of invention
The present invention relates to Liliaceae allium multiplieronion, non-volatile abstract, its preparation method and the said abstract that particularly relates to multiplieronion is used for losing weight in production, the application of the medicine of regulating blood lipoid, antiplatelet aggregation and arteriosclerosis.
The background of invention
In China, the compositions (abstract) of using plant derivation is as the history in existing thousands of years of therapeutic agent.In recent decades, along with biochemistry and pharmacology's continuous advancement in technology and the modern deep and popularization of Chinese traditional medicine, people might obtain different chemical substances from various natural plant materials separation, and get at further institute on the basis of the physiology of material and pharmacological activity, finishing screen is selected the medicine that can be used for preventing and/or treating disease, and then realizes corresponding plants (natural pharmaceutical resources) and by the large-scale industrial production of it deutero-abstract or monomer component.
Multiplieronion (Allium cepa L.var.agrogatum Don.) is a kind of Liliaceae Allium unifacial leaf herbaceous plant that originates in the Northeast of China.Former, among the people just have the small size plantation with this kind of plant as the edible also idol of vegetable.
To the research of multiplieronion only less than the vicennial time.1984, people such as Jiang Mantao at first separated from this plant and have obtained 15 kinds of volatile ingredients and identified that 8 kinds have platelet aggregation and thromboxane A
2The active sulfide of synthetic inhibition.Confirm that in experiment in vitro methacrylic trithio (MATS) wherein has interference effect (Jiang Mantao etc., Norman Bethune Medical University's journal, 10:609,1984) to the platelet arachidonic acid metabolic.Continue after, people such as Sun Qiliang have isolated from multiplieronion again to have blood pressure and reduces active prostaglandin A
1Monomer (Sun Qiliang etc., Chinese herbal medicine, 19:2,1988).
Above-mentioned these and other correlational studyes show, and are the same with other alliums that carried out fully research, and multiplieronion may also contain widely active substance and have bigger medical value equally.For this reason, the inventor is based on the experience of being engaged in the past multiplieronion research for many years, utilize active method for tracing further to separate and filtered out the multiple non-volatile abstract of multiplieronion, and the non-volatile abstract that has successfully prepared with multiplieronion is being used for prevention and treating hyperlipemia and obesity of primary activity composition, and have the pharmaceutical composition of arteriosclerosis and hypertension effect, thereby finished the present invention.
The purpose of invention
An object of the present invention is to provide the non-volatile abstract of the multiplieronion that consists essentially of flavone compound, steroidal compounds and nitrogen-containing compound.
Extract preferred embodiment according to the present invention, wherein said multiplieronion is the bulb of multiplieronion plant.
Extract preferred embodiment according to the present invention, wherein said multiplieronion is a multiplieronion Herb plant.
Extract preferred embodiment according to the present invention, wherein said flavone compound be selected from Quercetin, nimbecetin, Quercetin-4 '-oxygen-β-D-pyranglucoside, Quercetin-3,4 '-dioxy-β-D-pyranglucoside, Quercetin-3 '-oxygen-β-D-pyranglucoside and Quercetin-3 '-methoxyl group-4 '-oxygen-β-D-pyranglucoside.
Abstract preferred embodiment according to the present invention, wherein said steroidal compounds is selected from (25R)-Ruscogenin1-O-α-L-rhamnopyranosyl-(1 → 2)-α-L-arabinopyranoside, (25S)-Ruscogenin 1-O-α-L-rhamnopyranosyl-(1 → 2)-α-L-arabinopyranoside, (25R)-Ruscogenin 1-O-α-L-rhamnopyranosyl-(1 → 2)-β-D-galactopyranoside, (25S)-Ruscogenin 1-O-α-L-rhamnopyranosyl-(1 → 2)-β-D-galactopyranoside, daucosterol, cupreol.
Abstract preferred embodiment according to the present invention, wherein said nitrogen-containing compound are selected from N-(2-(4-hydroxy phenyl) ethyl)-3-(4-hydroxy phenyl)-2-acrylamide, 1,6-caprolactam.
Another object of the present invention provides the method for the non-volatile abstract of preparation multiplieronion, this method comprises: at first with alcohol dipping or reflux, extract, pretreated multiplieronion Herb plant and/or its bulb, perhaps the multiplieronion plant that directly will clean in advance and simply be cut into small pieces with distilled water and/or its bulb soak to squeeze the juice after 12-24 hour and filter with conventional method and collect soak.After collecting soak and reclaiming ethanol residue is crossed the adsorbent resin chromatographic column, obtain basically the non-volatile abstract of the multiplieronion formed by flavone compound, steroidal compounds and nitrogen-containing compound then with ethanol elution.
According to a preferred embodiment of the inventive method, wherein said adsorbent resin chromatographic column is selected from macroporous adsorbent resin, polyamide or polyacrylamide resin, silica gel, aluminium oxide or sephadex chromatography post.
According to a preferred embodiment of the inventive method, the ethanol that wherein is used for eluting is the ethanol water of 20-95%.
A further object of the present invention provides the non-volatile abstract of the multiplieronion that as above prepares and is producing reduction body weight and regulating blood lipoid, antiplatelet aggregation, and the application in arteriosclerosis and the hypertensive medicine.
Said application preferred embodiment according to the present invention, wherein the non-volatile abstract of said multiplieronion consists essentially of flavone compound, steroidal compounds and nitrogen-containing compound.
A further object of the present invention provides basically the pharmaceutical composition of being made up of the non-volatile extract of the as above multiplieronion of preparation and one or more pharmaceutically acceptable carriers or diluent.
Pharmaceutical composition preferred embodiment according to the present invention, wherein the non-volatile abstract of said multiplieronion comprises flavone compound, steroidal compounds and nitrogen-containing compound.
A further object of the present invention provides the crude extract of multiplieronion as the application of additive in producing functional food or other healthy Related products.
The detailed description of invention
The present invention relates to Liliaceae allium multiplieronion, the non-volatile abstract that particularly relates to multiplieronion, its preparation method and said abstract are being produced reduction body weight and regulating blood lipoid, antiplatelet aggregation, and the application in arteriosclerosis and the hypertensive medicine.
The Liliaceae allium is the edible vegetable with flavoring agent function mostly.Individual in the allium kind nearly more than 110 of China's discovery at present.The composition of allium is abundant and have a biological function widely.For example relevant with the pharmaceutical properties of allium that with the Bulbus Allii Cepae is representative main component is kind more than 100 nearly, and the biologic activity of known allium comprises but is not only limited to immunoregulatory activity, immunostimulatory activity, antiviral activity, antibacterium and antifungal activity, platelet aggregation inhibitory activity, and the blood fat reducing and the activity etc. that brings high blood pressure down.Clinical applicable medicine provides according to (referring to United States Patent (USP) 6,340, No. 483) for the effective component extracts with allium is developed to for these biologys of allium and pharmaceutical properties.
Yet,, still lack deep research and development at present for a found recently kind---the multiplieronion of Liliaceae allium.Before the present invention, though with inventor place laboratory is some composition that the seminar of representative has separated and identified multiplieronion, but biology and pharmacological activity to these and other compositions or " effective site " lack enough understandings, particularly " effective site " of multiplieronion are not developed to a kind of medicine or functional food for clinical practice so far fully.
Therefore, an object of the present invention is to provide the non-volatile abstract of the multiplieronion that consists essentially of flavone compound, steroidal compounds and nitrogen-containing compound.
According to the preferred embodiments of the invention, wherein said flavone compound comprise but be not only limited to Quercetin, nimbecetin, Quercetin-4 '-oxygen-β-D-pyranglucoside, Quercetin-3,4 '-dioxy-β-D-pyranglucoside, Quercetin-3 '-oxygen-β-D-pyranglucoside and Quercetin-3 '-methoxyl group-4 '-oxygen-β-D-pyranglucoside; Wherein said steroidal compounds comprises but is not only limited to (25R)-Ruscogenin 1-O-α-L-rhamnopyranosyl-(1 → 2)-α-L-arabinopyranoside, (25S)-Ruscogenin 1-O-α-L-rhamnopyranosyl-(1 → 2)-α-L-arabinopyranoside, (25R)-Ruscogenin 1-O-α-L-rhamnopyranosyl-(1 → 2)-β-D-galactopyranoside, (25S)-Ruscogenin 1-O-α-L-rhamnopyranosyl-(1 → 2)-β-D-galactopyranoside, daucosterol, cupreol; And wherein said nitrogen-containing compound comprises but is not only limited to N-(2-(4-hydroxy phenyl) ethyl)-3-(4-hydroxy phenyl)-2-acrylamide, 1,6-caprolactam.
Certainly, in the extract of the present invention except that containing above-mentioned these compositions, also can contain and some otherly be worth relevant composition with the pharmacology of extract, for example saccharide compound, other glycoside compounds, contain oxygen or sulphur compound, organic acid or mineral acid, lipid compounds, metal (for example selenium and ferrum etc.) and nonmetallic ion, and pectin, allicin and allin etc.Yet from they shared ratios extract, these chemical compounds are gone up substantially and can be ignored.
Another object of the present invention provides the method for the non-volatile abstract of preparation multiplieronion, this method comprises: multiplieronion plant and/or its bulb that cleans in advance with alcohol dipping or reflux, extract, at first, perhaps the multiplieronion plant that directly will clean in advance and simply be cut into small pieces with distilled water and/or its bulb soak to squeeze the juice after 12-24 hour and filter with conventional method and collect soak.After collecting lixiviating solution and reclaiming ethanol residue is crossed the adsorbent resin chromatographic column, promptly obtain basically the non-volatile abstract of the multiplieronion formed by flavone compound, steroidal compounds and nitrogen-containing compound then with ethanol elution.
More particularly, in order to prepare the extract of multiplieronion involatile constituent, multiplieronion plant and/or its bulb and the filtration collection filtrate of at first cleaning in advance and simply being cut into small pieces with ethanol merceration stain or heating and refluxing extraction.Under the situation of using ethanol merceration stain, the time of general dipping is about 1-3 days.And under the situation of using alcohol heating reflux to extract, then only need about 0.5-5 hour time to get final product.After reclaiming ethanol this residue is crossed the adsorbent resin chromatographic column, for example macroporous adsorptive resins and/or polyamide resin column and/or polyacrylamide resin post, silica gel, aluminium oxide or sephadex chromatography post.Behind the sample upper prop, wash post with deionized water in advance and shoal up to the effluent color.Then with the total flavones in thin layer chromatography method or ultraviolet detection method or the high-efficient liquid phase chromatogram technique monitoring eluent roughly under the situation of content, use the 20-95% ethanol elution with about 0.1-5ml/ minute flow velocity, the total flavones in eluent roughly content near till zero.Promptly obtain required extract after collecting eluent and reclaiming ethanol.
The multiplieronion plant that perhaps also can be at first will clean in advance and simply be cut into small pieces with distilled water and/or its bulb soak to squeeze the juice after 12-24 hour and filter with conventional method collects soak.Then soak is directly crossed adsorbent resin chromatographic column, for example macroporous adsorptive resins and/or polyamide resin column and/or polyacrylamide resin post, silica gel, aluminium oxide or sephadex chromatography post.Behind the sample upper prop, wash post with deionized water in advance and shoal up to the effluent color.Then with the total flavones in thin layer chromatography method or ultraviolet detection method or the high-efficient liquid phase chromatogram technique monitoring eluent roughly under the situation of content, use the 20-95% ethanol elution with about 0.1-5ml/ minute flow velocity, the total flavones in eluent roughly content near till zero.Promptly obtain required extract after collecting eluent and reclaiming ethanol.
According to the preferred embodiment of the inventive method, wherein said alcohol dipping and water retting step all can be finished under the ultrasound wave effect.
According to another preferred embodiment of the inventive method, wherein said adsorbent resin chromatographic column can be macroporous adsorbent resin, polyamide and polyacrylamide resin post, silica gel, aluminium oxide or sephadex chromatography post.
For medical value that confirms extract of the present invention and the feasibility of using as ingredient, we further use experimental alimentary obesity and hyperlipemia animal model (rat), have observed the as above biologic activity of the non-volatile abstract of the multiplieronion of preparation.Our experimental result shows that forcefully abstract of the present invention can reduce the blood lipid level of two kinds of animal patterns significantly and the body weight of animal is obviously alleviated.For example, compare with model control group, the serum triglycerides of experimental therapy treated animal and cholesterol levels performance have tangible reduction trend.In addition, compare with matched group, the average weight of accepting the experimental therapy treated animal of extract of the present invention in viewing duration significantly reduces, and the liver weight coefficient of these animals also shows reduction trend.
Therefore, based on our preliminary observation result, infer very possible use extract of the present invention as the primary activity composition, preparation is used to reduce body weight, regulating blood lipoid, antiplatelet aggregation, and arteriosclerosis and hypertensive medicine.
A further object of the present invention provides a kind of pharmaceutical composition of being made up of the non-volatile extract of multiplieronion of as above preparation and one or more pharmaceutically acceptable carriers or diluent basically.
Pharmaceutical composition preferred embodiment according to the present invention, wherein the non-volatile extract of said multiplieronion comprises flavone compound, steroidal compounds and nitrogen-containing compound.
Another preferred embodiment of pharmaceutical composition according to the present invention, said pharmaceutical composition also can contain one or more other have the natural of identical or assosting effect or a chemicals composition.For example said composition comprises but is not only limited to effective site and the extract of Radix Ginseng, Radix Salviae Miltiorrhizae, Radix Puerariae, Rhizoma Chuanxiong, Flos Carthami, Fructus Crataegi and Hirudo etc., the blood lipid-lowering medicine of chemosynthesis such as colestyramine, clofibrate, Ji Feibeite, lovastatin, bezafibrate, and hydroxycitric acid, L-carnitine, acetone acid etc. promote the medicine of fatty acid oxidation.
Pharmaceutical composition of the present invention not only can be used for preventing and treating the hyperlipemia that comprises hypercholesterolemia, hypertriglyceridemia, but also can be used for preventing and treat some and the dyslipidemia relevant other diseases that raises.These diseases include but are not limited to obesity, arteriosclerosis, hypertension, coronary heart disease, fatty liver and diabetes etc.
On the other hand, also can use the crude extract of multiplieronion, promptly the extract of the ethanol of multiplieronion and/or water is used to produce various functional foods or other healthy Related products as additive.
May pharmaceutical composition of the present invention be made tablet, capsule, pill, powder agent, suppository and solution and suspending agent according to known method in the pharmaceuticals industry.Wherein preferably be suitable for capsule and tablet through gastrointestinal administration.When preparation is suitable for the capsule, tablet, pill of oral administration and powder agent, can use sucrose, lactose, galactose, corn starch, gelatin, microcrystalline Cellulose, carboxymethyl cellulose etc. as carrier or excipient.
In addition, also can use in the pharmaceuticals industry known method and auxiliary element pharmaceutical composition of the present invention to be made solution and the suspending agent that is suitable for oral administration.In order to prepare solution or the suspending agent that is suitable for the outer administration of gastrointestinal tract, can use distilled water, water for injection, isotonic sodium chlorrde solution or glucose solution, perhaps low concentration (for example 1-100mM) phosphate buffered saline (PBS) (PBS) is as carrier or diluent.
Can add one or more other auxiliary elements or additives in the preparation of these gastrointestinal tract external administrations, for example can use ascorbic acid as antioxidant, use sodium benzoate etc. are as antiseptic.In the preparation of these dosage forms, can also contain other appropriate solubilizing agent, disintegrating agent, lubricant, coloring agent, dispersant or surfactant.
In general, the oral administration dosage of pharmaceutical composition of the present invention is 0.01 to 100mg/kg body weight/day, is preferably 0.1 to 50mg/kg body weight/day, is preferably 1 to 10mg/kg body weight/day.Yet more definite dosage should be determined by the clinician factors such as the sensitivity of used medicine and administering modes according to age of the character of disease to be treated or pathological state, the order of severity, patient, body weight, patient to be treated.
The following example is intended to further illustrate rather than limit the present invention.Under the prerequisite of the spirit and principles in the present invention, all will fall into the present invention and await the reply in the claim scope inventing any change that indivedual technical steps carry out and changing.
Embodiment
Embodiment 1: the preparation of multiplieronion involatile constituent abstract
This implementation example is described the method for preparation multiplieronion involatile constituent abstract of the present invention.
After water cleans the fresh multiplieronion of 5kg repeatedly 3 times and simply shreds, to wherein adding ethanol 500ml.Then this mixture was placed 72 hours at normal temperatures.After the lixiviate, conventional filtration is also collected resulting merceration extract.Evaporate recovery ethanol down till lixiviating solution does not almost have alcoholic acid abnormal smells from the patient in decompression.Then with macroporous resin column on the residue, the color that post is washed till effluent with distilled water shoals the back with 70% ethanol elution (flow velocity 3ml/ minute), monitors the roughly content of total flavones in the eluate simultaneously with thin layer chromatography.Treat promptly to stop eluting after eluate no longer contains flavone.After collecting eluent and reclaiming ethanol, dried residue obtains the 200g pale yellow powder.
Use standard substance in contrast, resulting extract is carried out qualitative and detection by quantitative with thin layer chromatography and ultraviolet detection method or high performance liquid chromatography.The result shows that the extract that as above obtains is made up of flavone compound, steroidal compounds and nitrogen-containing compound basically, and purity at least 50%.
Embodiment 2: multiplieronion extract of the present invention is to the antiobesity action of alimentary obesity rat model
72 qualified rats of screening are divided into 6 groups at random: normal control group, fat model group, multiplieronion extract (little, in, heavy dose) group and positive controls, 12 every group.Except that the normal control treated animal is accepted the normal diet, other each treated animals are all accepted high fat high heat feedstuff (every 100g normal feedstuff adds milk powder 10g, Adeps Sus domestica 10g, 1 in egg, white sugar 8g).Organize respectively during the nursing that rat all freely drinks water, diet, supply with feedstuff every day 2 times, form the alimentary obesity model behind the 45d.
Afterwards, all animals all recover to take food normal diet and beginning by following scheme administration: the multiplieronion extract is little, in, heavy dose of group rat irritates the stomach multiplieronion extract of the present invention (25,50,100mg/kg) that comes into operation every day; Positive controls is irritated and is raised known Weight-lossing hypolipemic medicine blood health fat 100mg/kg; Normal control group and fat model group are all irritated stomach isopyknic distilled water that comes into operation.Successive administration 15 days.The 16th day, measure and respectively organize rat body weight, with 3% pentobarbital sodium 30mg/kg intraperitoneal injection of anesthesia, the ventral aorta blood sampling, separation of serum is also measured T-CHOL (TC), triglyceride (TG), highdensity lipoprotein-cholesterol (HDL-c) and LDL-C (LDL-c) content.(X ± S) expression adopts two groups of comparison t check carrying out statistical analysiss to experimental data with mean ± standard deviation.Shown in the following tabulation 1 of result.
Table 1 multiplieronion abstract to the influence of alimentary obesity rat fat (X ± S, n=10)
| Group | TC(mmol/L) | TG(mmol/L) | HDL-c(mmol/L) | LDL-c(mmol/L) |
| The fat model group of normal control group | 1.08±0.52* 1.56±0.40 | 0.78±0.29* 1.18±0.37 | 0.43±0.07 0.33±0.10 | 0.77±0.23 0.84±0.36 |
| The multiplieronion abstract | ||||
| 25mg/kg 50mg/kg 100mg/kg | 1.49±0.68 1.12±0.41* 1.10±0.32* | 1.02±0.46 0.95±0.58 0.81±0.23* | 0.38±0.08 0.36±0.11 0.39±0.07 | 0.83±0.27 0.80±0.31 0.80±0.28 |
| Positive controls | ||||
| 100mg/kg | 1.17±0.67 | 0.93±0.49 | 0.35±0.05 | 0.79±0.34 |
Compare * p＜0.05 with fat model group
By the result shown in the table 1 as can be seen, come into operation multiplieronion extract of the present invention continuously after 15 days, serum TC of fat model group animal and TG are normal, and matched group obviously raises (p＜0.05), and HDL-c and LDL-c do not have significant change (p＞0.05).Compare with fat model group, heavy dose of treated animal serum TC of multiplieronion extract and TG all obviously reduce (p＜0.05), and middle dosage group serum TC obviously reduces (p＜0.05), and serum TG also has downward trend.
Experiment finishes the back and puts to death animal, separates behind the kidney of each treated animal and fat around the genitals, and the weight of these fatty tissuees relatively.Shown in the following tabulation 2 of result.
Table 2 multiplieronion abstract to the influence of alimentary obesity rat tissue fat weight (g, X ± S, n=10)
| Group | Fat behind the kidney | Fat around the genitals | Fat/body weight behind the kidney | Genitals fat/body weight | |
| The fat model group of normal control group | 3.10±1.08** 6.79±2.83 | 2.12±0.89** 4.69±1.75 | 0.013±0.008** 0.025±0.009 | 0.009±0.004** 0.017±0.005 | |
| The multiplieronion abstract | |||||
| 25mg/kg 50mg/kg 100mg/kg | 4.53±1.53* 4.52±1.64* 4.01±1.07** | 3.71±1.15 3.17±0.87* 2.96±0.69* | 0.021±0.012 0.017±0.006* 0.015±0.008* | 0.014±0.007 0.012±0.006* 0.011±0.003** | |
| Positive controls | |||||
| 100mg/kg | 4.70±1.12* | 3.34±0.98 | 0.019±0.007 | 0.012±0.003* | |
Compare * p＜0.05, * * p＜0.01 with fat model group
By the result shown in the table 2 as can be seen, fat behind the kidney of fat model group animal, around the genitals behind fat, the kidney fat/body weight and genitals fat/body weight ratio all normally matched group obviously increase (P＜0.01).Compare with fat model group, the above-mentioned four indices of the heavy dose of treated animal of neutralization of multiplieronion extract of coming into operation all significantly reduces (P＜0.05 or P＜0.01), and after the small dose group animal reproduction device fat/body weight, kidney behind fat and the kidney fat/body weight minimizing trend is all arranged.
The influence of multiplieronion extract to alimentary obesity rat body weight and liver weight coefficient further observed and write down in this research, shown in the following tabulation 3 of result.
Table 3 multiplieronion extract to the influence of the heavy coefficient of alimentary obesity rat body weight and liver (X ± S, n=10)
| Group | Liver weight coefficient (gram liver weight/100g body weight) | The weight of animals (g) |
| The fat model group of normal control group | 3.774±0.805 3.491±0.966 | 251±7.3*** 310±8.7 |
| The multiplieronion extract | ||
| 25mg/kg 50mg/kg 100mg/kg | 3.574±0.704 3.672±0.564 3.721±0.625 | 298±9.4** 292±8.9*** 281±9.3*** |
| Positive controls | ||
| 100mg/kg | 3.623±0.816 | 301±7.6* |
Compare * p＜0.05 with fat model group
By the result shown in the table 3 as can be seen, the normal matched group of the body weight of fat model group animal obviously increases (p＜0.001), and the liver weight coefficient has reduction trend (p＞0.05).Come into operation the multiplieronion extract little, in, the fatter model group of body weight of heavy dose of treated animal obviously reduces (p＜0.01 or p＜0.001), the liver weight coefficient then has increase trend.
Embodiment 3: multiplieronion extract of the present invention is to the blood lipid regulation effect of experimental hyperlipidemia rat model
Get 72 of Wistar rats, be divided into 6 groups at random, 12 every group.Normal control group: feed normal diet, give normal saline 2ml/kg; High fat matched group: feed high lipid food, give normal saline 2ml/kg; Positive controls: feed high lipid food and gavage lovastatin 20mg/kg; The multiplieronion extract is little, in, heavy dose of group: feed high lipid food, gavage multiplieronion extract 25,50,100mg/kg respectively.The high fat diet group begins in administration the previous day, give at dusk high lipid food (prescription: 2% cholesterol, 0.2% propylthiouracil, 0.3% sodium cholate, 7.5% Adeps Sus domestica, 90% normal diet) every night, every average 20g of Mus replenishes normal diet daytime, totally 15 days.
Each treated animal is all irritated stomach come into operation above-mentioned feedstuff or medicine, continuous 15 days the morning.In administration fasting in night in last 1 day, can't help water.Morning next day is with 3% pentobarbital sodium (30mg/kg) intraperitoneal injection of anesthesia animal, from ventral aorta blood sampling 3ml, separation of serum is also measured triglyceride (TG), T-CHOL (TC), HDL-C (HDL-c), low-density lipoprotein cholesterol (LDL-c), lipid peroxide (LPO) content and superoxide dismutase (SOD) activity by the described method of test kit (building up bio-engineering research by Nanjing is provided) description.Other 4ml that takes a blood sample, with 1% anticoagulant heparin, wherein 1ml add LBY-N6A self-cleaning rotary viscosimeter measure whole blood low cut (10/s), in cut (40/s), height is cut (120/s) viscosity.All the other 3ml blood are got upper plasma and are surveyed blood plasma 6-ketone-prostaglandin F with putting the method for exempting from (test kit is provided by Chinese People's Liberation Army General Hospital's East Asia immunological technique institute) with the centrifugal 10min of 3000 commentaries on classics/min
1a(PGI
2) and thromboxance B
2(TXA
2).Getting 1/2 liver puts in 10% formalin fixing to go fat stains, observation lipidosis situation.Other is 1/2 liver LPO to be measured and SOD.The result is respectively shown in the following tabulation 4-8.
Table 4 multiplieronion abstract to the influence of hyperlipidemia rats blood lipid metabolism (X ± S, n=10)
| Group | TG(mmol/L) | TC(mmol/L) | LDL-c(mmol/L) |
| The high fat matched group of normal control group | 0.62±0.27* 1.07±0.45 | 1.78±0.86*** 7.70±2.38 | 4.54±1.84* 7.21±2.34 |
| The multiplieronion abstract | |||
| 25mg/kg 50mg/kg 100mg/kg | 0.93±0.18 0.67±0.31* 0.56±0.15** | 6.85±2.02 4.97±1.87** 4.08±1.01*** | 6.34±2.03 5.81±1.23* 4.69±1.12** |
| Lovastatin | |||
| 20mg/kg | 0.66±0.28* | 4.98±1.20** | 4.57±1.03** |
Compare * p＜0.05, * * p＜0.01, * * * p＜0.001 with high fat matched group
Table 5 multiplieronion abstract to the influence of hyperlipidemia rats blood lipid metabolism (X ± S, n=10)
| Group | HDL-c(mmol/L) | TC/HDL-c(mmol/L) | LDL-c/HDL-c (mmol/L) | |
| The high fat matched group of normal control group | 1.04±0.37* 0.72±0.24 | 1.71±0.56*** 10.69±3.68 | 4.37±1.41*** 10.01±3.82 | |
| The multiplieronion abstract | ||||
| 25mg/kg 50mg/kg 100mg/kg | 0.83±0.27 0.99±0.16* 1.01±0.17** | 8.25±1.28 7.42±1.16** 7.28±1.29** | 7.64±2.01 5.87±1.86** 4.64±1.95*** | |
| Lovastatin | ||||
| 20mg/kg | 0.84±0.12 | 7.55±1.62* | 5.44±2.08** | |
Compare * p＜0.05, * * p＜0.01, * * * p＜0.001 with high fat matched group
By the data shown in table 4 and 5 as can be seen, the serum TC of high fat control animals, TG, LDL-c, TC/HDL-c and LDL-c/HDL-c all are significantly higher than normal control treated animal (P＜0.05 or P＜0.001), HDL-c then significantly falls in normal control group (P＜0.05), shows that hyperlipidemia model duplicates successfully.Compare with high fat control animals, the oral big or middle dosage tiller onion extract of animal (50,100mg/kg) back serum TC, TG, LDL-c, TC/HDL-c and LDL-c/HDL-c level all obviously reduce (P＜0.05, P＜0.01 or P＜0.001), then obviously rising (P＜0.05 or P＜0.01) of serum hdl-c level.
Table 6 multiplieronion abstract to the influence of hyperlipidemia rats serum and liver L PO and SOD (X ± S, n=10)
| Group | Serum | Liver | ||
| LPO(nmol/L) | SOD(U/L) | LPO(nmol/ml) | SOD(nu/mg) | |
| The high fat matched group of normal control group | 7.06±1.14** 8.80±1.01 | 463.2±42.9* 404.4±55.8 | 5.60±1.05* 6.98±1.30 | 9.26±0.91** 7.61±1.39 |
| The multiplieronion abstract | ||||
| 25mg/kg 50mg/kg 100mg/kg | 8.53±0.47 7.87±0.76* 7.12±1.05** | 427.7±44.0 452.8±35.8* 457.8±51.4* | 6.63±1.61 5.70±1.22* 5.42±1.02** | 8.05±1.78 9.15±1.13* 9.18±1.25* |
| Lovastatin | ||||
| 20mg/kg | 7.10±1.07** | 412.3±40.7 | 5.72±1.12* | 8.32±1.20 |
Compare * p＜0.05, * * p＜0.01 with high fat matched group
By the data shown in the table 6 as can be seen, compare with the normal control group, high fat control animals serum and liver L PO content obviously raise (P＜0.05 or P＜0.01), and active obviously reduce (P＜0.05 or P＜0.01) of SOD shows that hyperlipidemia rats is with the free radical lipid peroxidation injury.With high fat matched group relatively, the oral big or middle dosage multiplieronion extract of animal (50,100mg/kg) can make hyperlipidemia rats serum and liver L PO content obviously reduce (P＜0.05 or P＜0.01), SOD activity then obviously raise (P＜0.05).
Table 7 multiplieronion abstract to the influence of hyperlipidemia rats whole blood viscosity (X ± S, n=10)
| Group | Whole blood viscosity | |||||
| 10/s | 40/s | 120/s | ||||
| The high fat matched group of normal control group | 11.35±1.21* 13.32±2.30 | 4.56±0.39* 5.06±0.26 | 3.83±0.31* 4.34±0.53 | |||
| The multiplieronion abstract | ||||||
| 25mg/kg 50mg/kg 100mg/kg | 12.16±1.49 11.42±1.38* 11.25±1.21* | 4.83±0.36 4.98±0.73 4.69±0.47* | 3.90±0.27* 3.79±0.58* 3.73±0.32** | |||
| Lovastatin | ||||||
| 20mg/kg | 12.55±1.16 | 5.11±0.55 | 4.14±0.29 | |||
Compare * p＜0.05, * * p＜0.01 with high fat matched group
By the data shown in the table 7 as can be seen, the normal control group relatively, the whole blood of high fat control animals is low to be cut, in cut and height is cut viscosity and all obviously increased (P＜0.05), show that hyperlipidemia rats is with hemorheological change.Compare with high fat matched group, heavy dose of multiplieronion extract (100mg/kg) can obviously reduce whole blood lowly cut, in cut and height is cut viscosity (P＜0.05 or P＜0.01), in dosage multiplieronion extract (50mg/kg) can reduce obviously that whole blood is low to be cut and height is cut viscosity (P＜0.05), and low dose of multiplieronion extract (25mg/kg) only can reduce the whole blood height and cuts viscosity (P＜0.05).
Table 8 multiplieronion abstract is to hyperlipidemia rats blood plasma PGI
2And TXA
2The influence of level (X ± S, n=10)
| Group | PGI 2(pg/mL) | TXA 2(pg/mL) | PGI 2/TXA 2 |
| The high fat matched group of normal control group | 407.3±117.6* 280.9±88.5 | 264.9±79.4* 433.7±176.7 | 1.75±1.13* 0.73±0.32 |
| The multiplieronion abstract | |||
| 25mg/kg 50mg/kg 100mg/kg | 311.3±78.4 364.6±88.1* 383.8±76.6* | 364.5±91.3 276.3±95.6* 265.2±53.0** | 0.85±0.41 1.43±0.48** 1.52±0.78** |
| Lovastatin | |||
| 20mg/kg | 315.2±58.2 | 271.5±63.9* | 1.16±0.45* |
Compare * p＜0.05, * * p＜0.01 with high fat matched group
By the data shown in the table 8 as can be seen, compare the blood plasma TXA of high fat control animals with the normal control group
2Level obviously increases (P＜0.05), and PGI
2Level and PGI
2/ TXA
2Ratio all obviously reduces (P＜0.05), shows that hyperlipidemia model can produce TXA
2With PGI
2Between dysequilibrium.With high fat matched group relatively, the blood plasma PGI of oral big or middle dosage multiplieronion extract (50,100mg/kg) back animal
2Level obviously increases, and PGI
2/ TXA
2Ratio also obviously improves (P＜0.05 or P＜0.01), and blood plasma TXA
2Level then reduces.
At last, inventor's using-system method has been observed the influence of multiplieronion extract to hyperlipidemia rats hepatic tissue lipidosis.
Respectively organize the fixing section of liver specimens back row fat stains, observe hepatic tissue lipidosis situation.The result as seen, the hepatocyte of 10 animals of normal control group there is no steatosis (0/10); The all visible steatosis (10/10) of the hepatocyte of 10 animals of high fat matched group, and the hepatic cell fattydegeneration of taking each treated animal of big, the little multiplieronion extract of neutralization and taking the lovastatin treated animal is respectively 6/10,4/10,3/10,4/10, and fat vacuole obviously reduces.Through X
2Check, three dosage groups of multiplieronion extract and lovastatin group and high fat matched group comparing difference be (p＜0.05 or p＜0.01) significantly, shows that the multiplieronion extract can obviously suppress the deposition of hyperlipidemia rats liver fat.
Claims (4)
1. consist essentially of the involatile constituent abstract of the multiplieronion of flavone compound, steroidal compounds and nitrogen-containing compound, it is characterized in that described abstract prepares by the following method, this method comprises multiplieronion plant or its bulb that cleans in advance with alcohol dipping or reflux, extract,, after collecting extracting solution and reclaiming ethanol residue is crossed the adsorbent resin chromatographic column, obtain required abstract with the 20-95% ethanol elution then.
2. the preparation method of claim 1 abstract, this method comprises: the multiplieronion plant or its bulb that clean in advance with alcohol dipping or reflux, extract,, after collecting extracting solution and reclaiming ethanol residue is crossed the adsorbent resin chromatographic column, obtain required abstract with the 20-95% ethanol elution then.
3. according to the method for claim 2, wherein said adsorbent resin chromatographic column is selected from macroporous adsorbent resin, polyamide or polyacrylamide resin, silica gel, aluminium oxide or sephadex chromatography post.
The abstract of a claim 1 be used for losing weight in production, the application of the medicine of blood lipid regulation, antiplatelet aggregation and arteriosclerosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031270336A CN100374121C (en) | 2003-05-19 | 2003-05-19 | Tillering onion extract and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031270336A CN100374121C (en) | 2003-05-19 | 2003-05-19 | Tillering onion extract and its application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1548051A CN1548051A (en) | 2004-11-24 |
| CN100374121C true CN100374121C (en) | 2008-03-12 |
Family
ID=34322033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031270336A Expired - Fee Related CN100374121C (en) | 2003-05-19 | 2003-05-19 | Tillering onion extract and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100374121C (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008003226A1 (en) * | 2006-06-30 | 2008-01-10 | Jiemei Zhang | Caulis allii fistulosum extract and the use in modulating blood-lipids and lowering cholesterols thereof |
| CN102204703A (en) * | 2011-05-12 | 2011-10-05 | 陈秋明 | Small shallot oral liquid and preparation method thereof |
| CN103520451B (en) * | 2013-10-19 | 2015-08-05 | 杨晓虹 | A kind of multiplieronion compositions with effect for reducing blood fat |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1089152A (en) * | 1993-01-01 | 1994-07-13 | 郭如明 | Bulbus Allii Cepae is developed as the series of products of single and compound recipe |
| CN1147392A (en) * | 1995-10-09 | 1997-04-16 | 北京德高思壮混凝土技术有限责任公司 | Healthy capsule made of onion |
-
2003
- 2003-05-19 CN CNB031270336A patent/CN100374121C/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1089152A (en) * | 1993-01-01 | 1994-07-13 | 郭如明 | Bulbus Allii Cepae is developed as the series of products of single and compound recipe |
| CN1147392A (en) * | 1995-10-09 | 1997-04-16 | 北京德高思壮混凝土技术有限责任公司 | Healthy capsule made of onion |
Non-Patent Citations (2)
| Title |
|---|
| 分蘖葱头中新黄酮苷的结构鉴定. 杨晓红等.药学学报，第35卷第10期. 2000 * |
| 葱属植物化学及药理研究进展. 邹忠梅等.药学学报，第34卷第5期. 1999 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1548051A (en) | 2004-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1271083C (en) | Composition, extraction process and use of total triterpene sapogenin extracted from bamboo | |
| CN101810793B (en) | Application of corn stigma flavone in preparing medicament for curing hyperlipidemia | |
| CN102634441B (en) | A kind of preparation method of health-care vinegar | |
| CN110898090A (en) | Panax notoginseng flower total saponin and preparation method and application thereof | |
| AU2019202625A1 (en) | A medicinal composition of extract of seed of Emblica officinalis and method of preparing the same | |
| CN107648430A (en) | A kind of preparation method of the effective constituents of steroid saponin containing trilliaceae capsule preparations and its application in various kinds of drug is prepared | |
| CN109820959A (en) | A kind of dendrobium candidum extract and its application rich in flavone c-glycoside | |
| CN106798762A (en) | One Plant Extracts and its preparation method and application | |
| JP2001508777A (en) | Pine needle extract and its use | |
| CN100374121C (en) | Tillering onion extract and its application | |
| CN108785370A (en) | A kind of pharmaceutical composition for treating hyperlipemia and atherosclerosis | |
| CN104055947A (en) | Traditional Chinese medicine composition comprising grape extract products and preparation method thereof | |
| CN101333241B (en) | Process for extracting dioscin, preparation thereof and use | |
| CN102228666B (en) | Composition prepared from pine pollen and curcuma, preparation method thereof, and application of composition in preparing medicament for treating inflammatory bowel disease | |
| CN105456277B (en) | Application of the ganodenic acid acid activity position in preparing blood fat reducing health products and drug | |
| CN106822071B (en) | Chinese medicinal effective component for treating coronary heart disease and hyperlipidemia, its preparation method and method for separating effective component from the same | |
| CN1687092A (en) | General glycoside extractive of xanthium and preparation method | |
| CN103110680A (en) | Preparation method of total phenolic acid of erigeron breviscapus | |
| CN102430001B (en) | Compound rose-hip flavone preparation for preventing diabetes mellitus and preparation method thereof | |
| CN105596836B (en) | A kind of onion compositions extracted from gingko biloba leaves with effect for reducing blood fat | |
| KR20000007347A (en) | Treating material for diabetes manufactured by long living balloon flower extract | |
| US8980340B1 (en) | Medicinal composition of extract of seed of emblica officinalis and method of preparing the same | |
| Castellano et al. | Olive oil enriched with oleanolic acid, process for its preparation and use thereof | |
| CN110327392A (en) | Yi Zhong Wen Quince-sweet basil flavonid composition and the application in atherosclerosis | |
| CN114588227A (en) | Composition for reducing blood fat, preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: JI HUI Free format text: FORMER OWNER: YANG XIAOJIANG Effective date: 20050318 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20050318 Address after: 130021 therapeutic room, radiation injury, School of public health, Jilin University, 13 Xinmin Street, Jilin, Changchun, China Applicant after: Ji Hui Address before: Chaoyang District City, Guilin Road province Jilin 130021 Changchun Guilin Hutong dormitory building 2 unit 124 Xinmin Kyrgyzstan No. 304 box 011 Applicant before: Yang Xiaohong |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: YANG XIAOHONG Free format text: FORMER OWNER: JI HUI Effective date: 20130628 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20130628 Address after: 130021 No. 1266, Fujin Road, Changchun, Jilin Patentee after: Yang Xiaohong Address before: 130021 therapeutic room, radiation injury, School of public health, Jilin University, 13 Xinmin Street, Jilin, Changchun, China Patentee before: Ji Hui |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080312 Termination date: 20160519 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |